New critical raw materials to the in-vitro diagnostic industry – Monkeypox Virus

It is a very exciting time for Aalto Bio Reagents, part of the Biosynth group. With the launch last week of two new peptides for Monkeypox Virus- (MPV) B21R- and B21R-B – BSA conjugate, the team are again at the forefront of providing critical reagents for diagnostics of emerging and impactful diseases.

The development of a standard antibody test for MPV is complicated by cross-reactive immune responses induced by vaccina, the virus used in smallpox vaccines. Aalto Bio Reagents’ new MPV peptides are essential for discerning MPV infection from other pox – part of their commitment to having novel and accurate reagents available for clinicians to test for emerging diseases.

 

 

The recognition is based on the surface glycoprotein B21R. This region contains important antibody targets as well as several key immunodominant epitopes. When peptides from this region are conjugated to a carrier protein like BSA, it greatly improves both the sensitivity of the assay compared to unconjugated peptide, and enhances stability – giving specificity, sensitivity and stability in one assay.

As of 2nd October 2022, approximately 70,000 cases of Monkeypox have been reported from 106 countries this year according to the World Health Organisation (WHO), prompting them to declare the outbreak “a public health emergency of international concern”. It is important to the team to continue to develop and supply critical raw materials for diagnosing these diseases. 

 

Find out more about the range of reagents for IVD available. 
Read more about this new development on Aalto Bio Reagents’ News page

 Contact the expert team to find out more